<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: products which", fill: "#f77fbe"},
{source: "8: products which", target: "8: technological", fill: "#f77fbe"},
{source: "8: technological", target: "8: new product introductions", fill: "#f77fbe"},
{source: "8: new product introductions", target: "8: developments", fill: "#f77fbe"},
{source: "8: developments", target: "8: which would", fill: "#f77fbe"},
{source: "8: products which", target: "9: Furthermore ", fill: "#e1a95f"},
{source: "9: Furthermore ", target: "9: competitors may", fill: "#e1a95f"},
{source: "9: competitors may", target: "9: marketing technologies andor", fill: "#e1a95f"},
{source: "9: marketing technologies andor", target: "9: andor commercially", fill: "#e1a95f"},
{source: "9: andor commercially", target: "9: attractive than ours", fill: "#e1a95f"},
{source: "9: Furthermore ", target: "10: success will depend", fill: "#f99"},
{source: "10: success will depend", target: "10: timely manner", fill: "#f99"},
{source: "10: success will depend", target: "12: dependent", fill: "#0ff"},
{source: "12: dependent", target: "12: North American ", fill: "#0ff"},
{source: "12: North American ", target: "12: distributor", fill: "#0ff"},
{source: "12: distributor", target: "12: significant", fill: "#0ff"},
{source: "12: significant", target: "12: significant reduction", fill: "#0ff"},
{source: "12: significant reduction", target: "12: sales volume", fill: "#0ff"},
{source: "12: sales volume", target: "12: distributor could", fill: "#0ff"},
{source: "12: dependent", target: "16: cannot assure", fill: "#a50b5e"},
{source: "16: cannot assure", target: "16: Patterson ", fill: "#a50b5e"},
{source: "16: Patterson ", target: "16: will purchase", fill: "#a50b5e"},
{source: "16: will purchase", target: "16: minimum quantity", fill: "#a50b5e"},
{source: "16: minimum quantity", target: "16: products from us", fill: "#a50b5e"},
{source: "16: products from us", target: "16: will continue", fill: "#a50b5e"},
{source: "16: will continue", target: "16: products at", fill: "#a50b5e"},
{source: "16: cannot assure", target: "17: If Patterson ", fill: "#fdf5e6"},
{source: "17: If Patterson ", target: "17: significant", fill: "#fdf5e6"},
{source: "17: significant", target: "17: product from us", fill: "#fdf5e6"},
{source: "17: If Patterson ", target: "27: Moreover ", fill: "#4b5320"},
{source: "27: Moreover ", target: "27: regulatory approval", fill: "#4b5320"},
{source: "27: regulatory approval", target: "27: requirements", fill: "#4b5320"},
{source: "27: Moreover ", target: "42: insurance coverage", fill: "#ff0038"},
{source: "42: insurance coverage", target: "42: potential liabilities", fill: "#ff0038"},
{source: "42: insurance coverage", target: "57: cannot assure", fill: "#a9203e"},
{source: "57: cannot assure", target: "57: proprietary", fill: "#a9203e"},
{source: "57: proprietary", target: "57: technologies will", fill: "#a9203e"},
{source: "57: technologies will", target: "57: obsolete as", fill: "#a9203e"},
{source: "57: obsolete as", target: "57: technological", fill: "#a9203e"},
{source: "57: technological", target: "57: introductions", fill: "#a9203e"},
{source: "57: introductions", target: "57: economic return on", fill: "#a9203e"},
{source: "57: economic return on", target: "57: investment", fill: "#a9203e"},
{source: "57: investment", target: "57: product development", fill: "#a9203e"},
{source: "57: cannot assure", target: "62: competitors", fill: "#20b2aa"},
{source: "62: competitors", target: "62: potential competitors", fill: "#20b2aa"},
{source: "62: potential competitors", target: "62: companies with substantially greater", fill: "#20b2aa"},
{source: "62: companies with substantially greater", target: "62: financial sales", fill: "#20b2aa"},
{source: "62: financial sales", target: "62: marketing technical", fill: "#20b2aa"},
{source: "62: marketing technical", target: "62: substantially greater", fill: "#20b2aa"},
{source: "62: substantially greater", target: "62: resources larger", fill: "#20b2aa"},
{source: "62: resources larger", target: "62: development staffs", fill: "#20b2aa"},
{source: "62: development staffs", target: "62: facilities", fill: "#20b2aa"},
{source: "62: facilities", target: "62: regulatory", fill: "#20b2aa"},
{source: "62: regulatory", target: "62: marketing products than", fill: "#20b2aa"},
{source: "62: competitors", target: "65: inability", fill: "#ff5349"},
{source: "65: inability", target: "65: successfully", fill: "#ff5349"},
{source: "65: successfully", target: "65: development by", fill: "#ff5349"},
{source: "65: development by", target: "65: competitors", fill: "#ff5349"},
{source: "65: competitors", target: "65: technology", fill: "#ff5349"},
{source: "65: inability", target: "70: availability", fill: "#ff0"},
{source: "70: availability", target: "70: components may", fill: "#ff0"},
{source: "70: components may", target: "70: interruptions", fill: "#ff0"},
{source: "70: interruptions", target: "70: market conditions", fill: "#ff0"},
{source: "70: availability", target: "133: fluctuations", fill: "#00703c"},
{source: "133: fluctuations", target: "133: operations could", fill: "#00703c"},
{source: "133: operations could", target: "133: adversely affect", fill: "#00703c"},
{source: "133: adversely affect", target: "133: market price", fill: "#00703c"},
{source: "133: market price", target: "133: Common Stock", fill: "#00703c"},
{source: "133: fluctuations", target: "START_HERE", fill: "#00703c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Defense_Production_Act_of_1950">Defense Production Act of 1950</a></td>
      <td>The Defense Production Act of 1950 (Pub.L. 81–774) is a United States federal law enacted on September 8, 1950 in response to the start of the Korean War. It was part of a broad civil defense and war mobilization effort in the context of the Cold War.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Alisher_Usmanov">Alisher Usmanov</a></td>
      <td>Alisher Burkhanovich Usmanov (Russian: Алишер Бурханович Усманов; born 9 September 1953) is an Uzbek-born Russian businessman and oligarch. By 2022, Usmanov had an estimated net worth of $19.5 billion and was among the world's 100 wealthiest people.Usmanov made his wealth after the collapse of the Soviet Union, through metal and mining operations, and investments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2011_military_intervention_in_Libya">2011 military intervention in Libya</a></td>
      <td>On 19 March 2011, a multi-state NATO-led coalition began a military intervention in Libya, to implement United Nations Security Council Resolution 1973, in response to events during the First Libyan Civil War. With ten votes in favour and five abstentions, the UN Security Council's intent was to have "an immediate ceasefire in Libya, including an end to the current attacks against civilians, which it said might constitute "crimes against humanity" ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/What's_Your_Raashee?">What's Your Raashee?</a></td>
      <td>What's Your Raashee? (lit. 'What's Your Zodiac Sign?') is a 2009 Indian Hindi-language romantic comedy film written and directed by Ashutosh Gowariker.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. Artificial intelligence, Blockchain, Cloud computing, and big Data are regarded as the "ABCD" (four key areas) of FinTech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Price">Price</a></td>
      <td>A prince is a male ruler (ranked below a king, grand prince, and grand duke) or a male member of a monarch's or former monarch's family. Prince is also a title of nobility (often highest), often hereditary, in some European states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_trend">Market trend</a></td>
      <td>A market trend is a perceived tendency of financial markets to move in a particular direction over time. These trends are classified as secular for long time frames, primary for medium time frames, and secondary for short time frames.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Volatility_(finance)">Volatility (finance)</a></td>
      <td>In finance, volatility (usually denoted by σ) is the degree of variation of a trading price series over time, usually measured by the standard deviation of logarithmic returns.\nHistoric volatility measures a time series of past market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SCHICK TECHNOLOGIES INC      ITEM 1A RISK FACTORS       Forward-Looking Statements       The  statements  contained  in  this Form 10-K include forward-looking     <font color="blue">statements within</font> the meaning of the Private Securities Litigation Reform     Act of 1995 (“PSLRA”)</td>
    </tr>
    <tr>
      <td>When used in this Form 10-K and in <font color="blue"><font color="blue">future filings</font> by</font>     the Company with the Securities and Exchange Commission, in the Company’s     press  releases, presentations to stockholders, securities analysts or     investors,  or  in  <font color="blue">oral statements</font> made by or with the approval of an     <font color="blue">executive officer</font> of the Company, the words or phrases “believes,” “may,”     “will likely result,” “estimates,” “projects,” “anticipates,” “expects” or     similar <font color="blue">expressions</font> and <font color="blue">variations</font> thereof are intended to identify such     forward-looking statements</td>
    </tr>
    <tr>
      <td>Any forward-looking statement involves risks and     <font color="blue">uncertainties</font> that may have a material adverse effect         10       ______________________________________________________________________         on the business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font> or prospects,     financial  or other, of the Company and may cause the Company’s actual     results  to  differ  <font color="blue">materially from historical</font> results or the results     discussed in the forward-looking statements</td>
    </tr>
    <tr>
      <td>The  <font color="blue">following discussions contain <font color="blue">cautionary statements</font></font> regarding the     Company’s business that investors and <font color="blue">others should carefully</font> consider</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>discussion is intended to take advantage of the “safe harbor” provisions of     the  PSLRA  In making these <font color="blue">cautionary statements</font>, the Company is not     undertaking  to  address  or  update  each factor in <font color="blue">future filings</font> or     <font color="blue">communications</font> regarding the Company’s business or results</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> a small number of products for most of our revenue, and     our <font color="blue">revenues could <font color="blue">significant</font>ly decrease</font> if any of these products are     rendered obsolete or inferior</td>
    </tr>
    <tr>
      <td>Our revenues are <font color="blue">primarily generated from sales</font> of our suite of CDR® dental     <font color="blue">imaging products</font> and, to a lesser extent, from our sales of other products</td>
    </tr>
    <tr>
      <td>These products, or any of the <font color="blue">products which</font> we may sell in the future,     could be rendered obsolete or inferior as a result of <font color="blue">technological</font> change,     changing customer needs, <font color="blue">new product <font color="blue">introduction</font>s</font> or other <font color="blue"><font color="blue">development</font>s</font>,     each of <font color="blue">which would</font> have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Furthermore, our     <font color="blue"><font color="blue">competitors</font> may</font> succeed in developing or marketing <font color="blue">technologies</font> and/or     products that are superior to and/or commercially more <font color="blue">attractive than ours</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to improve and enhance our     products in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">dependent</font>  upon an exclusive <font color="blue">North American </font><font color="blue">distributor</font> for a     <font color="blue">significant</font> portion of our revenue, and the loss or <font color="blue">significant</font> reduction in     the <font color="blue">sales volume</font> of this <font color="blue">distributor</font> could have a material adverse effect on     us</td>
    </tr>
    <tr>
      <td><font color="blue">Since May </font>1, 2000, we have marketed and <font color="blue">distributed</font> our CDR® <font color="blue">product line</font> in     the <font color="blue"><font color="blue"><font color="blue">United States</font> </font>and Canada </font><font color="blue">exclusively through</font> <font color="blue">Patterson </font>Dental Company     (“Patterson”)</td>
    </tr>
    <tr>
      <td>From fiscal 2002 through 2006, <font color="blue">Patterson </font>was the single     <font color="blue">largest contributor</font> to our revenues, and we anticipate that <font color="blue">Patterson </font>will     continue to be the single <font color="blue">largest contributor</font> to our revenues in the coming     <font color="blue">fiscal year</font></td>
    </tr>
    <tr>
      <td>During fiscal 2006, the <font color="blue">Agreement </font>was <font color="blue">extended through</font> <font color="blue">December     </font>2007</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">Patterson </font><font color="blue">will purchase</font> any specified     <font color="blue">minimum quantity</font> of <font color="blue">products from us</font> or that it <font color="blue">will continue</font> to purchase     any <font color="blue">products at</font> all from us</td>
    </tr>
    <tr>
      <td>If <font color="blue">Patterson </font>fails to purchase a <font color="blue">significant</font>     volume of <font color="blue">product from us</font>, it could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> third-party <font color="blue">distributor</font>s outside of North America, and     the loss or <font color="blue">significant</font> reduction in the <font color="blue">sales volume</font> of one or more of     those <font color="blue">distributor</font>s could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Outside of North America, we distribute our products through third-party     in<font color="blue">dependent</font> <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>Historically, a limited number of <font color="blue">distributor</font>s     have accounted for a <font color="blue">significant</font> portion of our revenues</td>
    </tr>
    <tr>
      <td>In general, these     <font color="blue">distributor</font>s could <font color="blue">discontinue</font> marketing our <font color="blue">products with</font> little or no     notice to us</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">distributor</font>s also could market <font color="blue">products which</font>     compete with ours</td>
    </tr>
    <tr>
      <td>The loss of or <font color="blue">significant</font> reduction in the <font color="blue">sales volume</font>     of one or more of our <font color="blue">distributor</font>s could have a material adverse effect on     us</td>
    </tr>
    <tr>
      <td>Since we operate in <font color="blue">markets outside</font> of the <font color="blue">United States</font>, we are subject to     <font color="blue"><font color="blue">additional</font> risks</font></td>
    </tr>
    <tr>
      <td>In fiscal 2006, 2005 and 2004, our sales to <font color="blue">customers outside</font> of the United     States were approximately 23prca, 27prca and 25prca, respectively, of our revenues,     and we anticipate that <font color="blue">international</font> sales <font color="blue">will continue</font> to account for a     <font color="blue">significant</font> percentage of our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>revenues are subject     to a number of <font color="blue">uncertainties</font>, including but not limited to the following:     <font color="blue"><font color="blue">agreements</font> may</font> be <font color="blue">difficult</font> to enforce and receivables <font color="blue">difficult</font> to collect;     <font color="blue">foreign customers</font> and <font color="blue">distributor</font>s may have <font color="blue">relatively long payment cycles</font>;     <font color="blue"><font color="blue">foreign countries</font> may</font> impose <font color="blue">additional</font> withholding taxes or otherwise tax     our foreign income, impose tariffs or adopt other <font color="blue"><font color="blue">restrictions</font> on foreign</font>     trade; <font color="blue">fluctuations</font> in <font color="blue">exchange rates may affect product demand</font>; United     States <font color="blue">export licenses may</font> be <font color="blue">difficult</font> to obtain; and <font color="blue">intellectual property</font>     rights in <font color="blue"><font color="blue">foreign countries</font> may</font> be <font color="blue">difficult</font> or impossible to enforce</td>
    </tr>
    <tr>
      <td>Moreover,  many  foreign  countries have their own <font color="blue"><font color="blue">regulatory</font> approval</font>     <font color="blue">requirements</font> for the sale of our products</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">introduction</font> of     <font color="blue">new products</font> into <font color="blue">international</font> markets could be prevented and/or costly     and/or time-consuming, and we <font color="blue">cannot assure</font> you that we will be able to     obtain the required <font color="blue"><font color="blue">regulatory</font> approval</font>s on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>We     also <font color="blue">cannot assure</font> you that any of these <font color="blue">factors will</font> not have a material     adverse effect on us</td>
    </tr>
    <tr>
      <td>Any failure to complete the <font color="blue">proposed <font color="blue">transaction</font></font> between us and Sirona     Dental Systems or a delay in the <font color="blue">completion</font> of the <font color="blue">proposed <font color="blue">transaction</font></font>     could cause us to incur substantial costs and <font color="blue">negatively affect</font> our results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>11       ______________________________________________________________________           If the proposed <font color="blue">combination</font> of our Company and Sirona Dental Systems, which     is to be <font color="blue">voted upon at</font> a <font color="blue">Special Shareholders Meeting </font>scheduled for June 14,     2006, is not completed on a <font color="blue">timely basis</font> or at all, we may suffer negative     <font color="blue">consequences</font> to our business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and     prospects, including, among others, incurring substantial fees and expenses     related  to  the  <font color="blue">combination</font> (including legal and <font color="blue"><font color="blue">accounting</font> fees</font> and     disbursements), <font color="blue">which must</font> be paid even if the <font color="blue">combination</font> is not completed;     and if the <font color="blue">Agreement </font>with Sirona is terminated and our board of <font color="blue">directors</font>     determines to pursue another <font color="blue">transaction</font>, it may not be able to find a     partner  at all or <font color="blue">on terms as attractive as</font> those provided for in the     <font color="blue">agreement with</font> Sirona</td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">key <font color="blue">management</font> personnel</font> or are unable to attract and retain     <font color="blue">qualified personnel</font>, it could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font>, in part, upon our ability to hire and retain     <font color="blue">management</font>, sales, technical, research and other personnel who are in high     demand and are often subject to <font color="blue">competing employment opportunities</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font> to hire or retain key <font color="blue">management</font>, sales, technical, research or     other <font color="blue">personnel could</font> have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>At the current     time, only two of our <font color="blue">executive officer</font>s, <font color="blue">the Chief Executive Officer </font>and     the Executive Vice President, are <font color="blue">employed pursuant</font> to <font color="blue">written employment</font>     <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>We  cannot  assure you that they or that any of our other     employees <font color="blue">will continue</font> to be <font color="blue">active with us</font></td>
    </tr>
    <tr>
      <td>We may be a party to <font color="blue">legal actions</font> that are not <font color="blue"><font color="blue">covered by</font> insurance</font></td>
    </tr>
    <tr>
      <td>We may be a party to a variety of <font color="blue">legal actions</font>, such as employment and     employment discrimination-related suits, employee benefit claims, breach of     contract   actions,   tort  claims,  <font color="blue">shareholder</font>  suits,  <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">investigations</font> and <font color="blue">intellectual property</font> related <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, we     could be subject to a variety of <font color="blue">legal actions</font> relating to our business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Recent <font color="blue">court decisions</font> and <font color="blue">legislative activity may increase</font> our     exposure  for any of these types of claims</td>
    </tr>
    <tr>
      <td>In some cases, substantial     <font color="blue">punitive damages could</font> be sought</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">insurance coverage</font> for     some of these <font color="blue">potential liabilities</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">potential liabilities</font> may not be     covered  by insurance, insurers may dispute coverage, or the amount of     <font color="blue">insurance may</font> not be sufficient to cover the <font color="blue">damages awarded</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">certain types</font> of damages, such as punitive damages, may not be <font color="blue">covered by</font>     insurance and <font color="blue">insurance coverage</font> for all or <font color="blue">certain forms</font> of <font color="blue"><font color="blue">liability</font> may</font>     <font color="blue">become unavailable</font> or <font color="blue">prohibitively expensive</font> in the future</td>
    </tr>
    <tr>
      <td>We must develop <font color="blue">new products</font> and <font color="blue">enhancements</font> to <font color="blue">existing products</font> in order     to  <font color="blue">remain competitive</font>, and our failure to do so could have a material     adverse effect on us</td>
    </tr>
    <tr>
      <td>We are currently developing <font color="blue">new products</font> and <font color="blue">enhancements</font> to our existing     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will initiate, continue with and/or     succeed in our efforts to develop or <font color="blue">enhance <font color="blue">such products</font></font></td>
    </tr>
    <tr>
      <td>We expect to     file 510(k) <font color="blue">applications</font> with the FDA in <font color="blue">connection</font> with our <font color="blue">future products</font>     and certain of our future product <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we     will file <font color="blue">applications</font> for or obtain <font color="blue"><font color="blue">regulatory</font> approval</font> from the FDA,     either in the form of a pre-market clearance or a 510(k) clearance, for any     of our <font color="blue">future products</font>, or that in order to obtain FDA clearance, we will     not  be  required  to  submit  <font color="blue">additional</font>  data or meet <font color="blue">additional</font> FDA     <font color="blue">requirements</font> that <font color="blue">may <font color="blue">substantially</font> delay</font> the <font color="blue">application process</font> and result     in substantial <font color="blue">additional</font> expense</td>
    </tr>
    <tr>
      <td>Moreover, such pre-market clearance, if     obtained, may be subject to <font color="blue">conditions on marketing</font> or <font color="blue"><font color="blue">manufacturing</font> which</font>     <font color="blue">could impede</font> our ability to <font color="blue">manufacture</font> and/or market our products</td>
    </tr>
    <tr>
      <td>While we     are engaged in research and <font color="blue">development</font> of <font color="blue">new products</font>, we <font color="blue">cannot assure</font>     you that we will be successful in <font color="blue">such endeavors</font></td>
    </tr>
    <tr>
      <td>There can be no assurance     that  any <font color="blue">products which</font> we may develop will be <font color="blue">approved by</font> or receive     marketing  clearance  from  applicable  domestic  and/or <font color="blue">international</font>     <font color="blue"><font color="blue">government</font>al</font> or <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>If we are unable to develop, obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for and market <font color="blue">new products</font> and <font color="blue">enhancements</font> to existing     products, it will have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Our business may be <font color="blue">negatively affect</font>ed if we do not continue to adapt to     rapid <font color="blue">technological</font> change, <font color="blue">evolving industry standards</font> and new product     <font color="blue">introduction</font>s</td>
    </tr>
    <tr>
      <td>The  market for our products is <font color="blue">characterized by rapid</font> and <font color="blue">significant</font>     <font color="blue">technological</font>  change,  evolving  industry  standards  and new product     <font color="blue">introduction</font>s</td>
    </tr>
    <tr>
      <td>Our  products  require  <font color="blue">significant</font>  planning, design,     <font color="blue">development</font> and <font color="blue">testing which</font> require <font color="blue">significant</font> capital commitments and     <font color="blue"><font color="blue">investment</font> by us</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our products or <font color="blue">proprietary</font>     <font color="blue"><font color="blue">technologies</font> will</font> not become <font color="blue">noncompetitive</font> or <font color="blue">obsolete as</font> a result of     <font color="blue">technological</font>  change,  evolving  industry  standards  or  new product     <font color="blue">introduction</font>s or that we will be able to generate any <font color="blue">economic return on</font> our     <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If our products or <font color="blue"><font color="blue">technologies</font> become</font>     <font color="blue">noncompetitive</font> or obsolete, it would have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>12       ______________________________________________________________________           <font color="blue">Competition </font>in the market is intense and we may not be able to compete     <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>relating to our <font color="blue">current products</font> is intense and includes various     companies, both within and outside of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We anticipate that     <font color="blue">competition</font> for our <font color="blue">future products</font> will also be intense and include various     companies, both within and outside of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> and     potential <font color="blue">competitors</font> include large <font color="blue">companies with <font color="blue"><font color="blue">substantially</font> greater</font></font>     financial, sales and marketing, technical and other resources, larger and     more experienced research and <font color="blue">development</font> staffs, more extensive physical     <font color="blue">facilities</font> and <font color="blue"><font color="blue">substantially</font> greater</font> experience in obtaining <font color="blue">regulatory</font>     approvals and in <font color="blue">marketing products than</font> we have</td>
    </tr>
    <tr>
      <td>In addition, we cannot     assure you that our <font color="blue">competitors</font> are not currently developing, or will not     attempt to develop, <font color="blue">technologies</font> and products that are more <font color="blue">effective than</font>     those being developed by us or that <font color="blue">would otherwise</font> render our existing and     <font color="blue">new <font color="blue">technology</font></font> and <font color="blue">products obsolete</font> or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that we will be able to <font color="blue">compete <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to compete     <font color="blue">successfully</font>  or  the <font color="blue">development</font> by our <font color="blue">competitors</font> of <font color="blue">technology</font> and     products that is more <font color="blue">effective than</font> those being developed by us would have     a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> upon a limited number of suppliers for <font color="blue">critical <font color="blue">components</font></font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">suppliers delay</font> or <font color="blue">discontinue</font> the <font color="blue">manufacture</font> of these <font color="blue">components</font>,     we  could  experience  <font color="blue">significant</font> delays in our shipment of products,     <font color="blue">increased costs</font>, and <font color="blue">cancellation</font> of orders for our products and damage to     our reputation</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">key suppliers</font></font> for various <font color="blue">critical <font color="blue">components</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">procure certain</font>     <font color="blue">components</font>, including the substantial majority of the <font color="blue">sensor chips used</font> in     our <font color="blue">manufacturing</font> process, from outside sources which are <font color="blue">sole suppliers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> and price of these <font color="blue">components</font> may be subject to change due     to <font color="blue">interruptions</font> in production, changing <font color="blue">market conditions</font> and other events</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">availability</font> may be <font color="blue">adversely impacted</font> if we fail to make     <font color="blue">timely payments</font> to our <font color="blue">key suppliers</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we would be     able to <font color="blue">enter into purchase arrangements with</font> other suppliers, or that if we     were to do so, <font color="blue">such suppliers would</font> be able to deliver such <font color="blue">components</font> at an     acceptable price or in a <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td>If we were unable to     develop reasonably-priced alternative sources in a <font color="blue">timely manner</font>, or if we     <font color="blue">encountered delays</font> or other <font color="blue">difficult</font>ies in the supply of <font color="blue">such products</font> and     other materials from third parties, there could be a material adverse effect     on us, including damage to our reputation</td>
    </tr>
    <tr>
      <td>In past years, semiconductors     have been subject to <font color="blue">significant</font> price <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>While we have, in the     past, attempted to mitigate the effects of <font color="blue">such potential <font color="blue">fluctuations</font></font>, we     <font color="blue">cannot assure</font> you that we <font color="blue">will continue</font> to do so or that we will be able to     <font color="blue">successfully</font> mitigate the effect of <font color="blue">future price increases on</font> our results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents may</font> not provide us with sufficient protection from infringement     by others; our exclusive right to sublicense certain <font color="blue">intellectual property</font>     related to CMOS <font color="blue">technology</font> is subject to <font color="blue">certain rights</font> to <font color="blue">use by others</font>,     and our <font color="blue">products may infringe on</font> the <font color="blue">intellectual property</font> rights of others</td>
    </tr>
    <tr>
      <td>We currently have issued and <font color="blue">allowed patents</font> and patent <font color="blue">applications</font>, as     described  in Item 1 -- “Business,” of this Form 10-K There can be no     assurance that any of our patents, any of the patents of which we are a     licensee or any <font color="blue">patents which may</font> be issued to us or which we may license in     the  future, will provide us with a <font color="blue">competitive advantage</font> or <font color="blue">afford us</font>     <font color="blue">protection against infringement by others</font>, or that the <font color="blue">patents will</font> not be     <font color="blue">successfully</font> challenged or <font color="blue">circumvented by third parties</font>, including our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We  are  the  exclusive  sub-licensee  for  use in <font color="blue">medical radiography</font>     <font color="blue">applications</font> of certain patents, patent <font color="blue">applications</font> and other know-how     related to complementary metal oxide semiconductor active pixel sensor     <font color="blue">technology</font> (the “APS Technology”), which was developed by the California     Institute of Technology and sublicensed to us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">exclusive rights</font> to such     <font color="blue">technology</font>  are  subject  to  <font color="blue">government</font>  rights to use, noncommercial     <font color="blue">educational</font> and <font color="blue">research rights</font> to use by <font color="blue">California Institute of Technology </font>    and the Jet Propulsion Laboratory, and the right of a <font color="blue">third party</font> to obtain     a <font color="blue"><font color="blue">nonexclusive license</font> from</font> the <font color="blue">California Institute of Technology </font>with     respect to such <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We believe that, except for such <font color="blue">third party</font>’s     exercise of its right to obtain a <font color="blue">nonexclusive license</font> to use <font color="blue">APS Technology </font>    in a field other than <font color="blue">medical radiography</font>, none of the <font color="blue">foregoing parties</font>     have given notice of their exercise of any of their <font color="blue">respective rights</font> to the     APS Technology</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that this <font color="blue">will continue</font> to be the case,     and any <font color="blue">such exercise could</font> have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We are also the owner of certain trade secrets, which we seek to <font color="blue">protect by</font>,     among  other  things,  entering  into non-disclosure, <font color="blue">confidentiality</font>,     non-solicitation and non-<font color="blue">competition</font> <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font>     you  that  the <font color="blue">duties imposed by</font> these <font color="blue">agreements</font>, such as the duty to     maintain <font color="blue">confidentiality</font> and the duty not to compete, will not be breached,     or that <font color="blue">such breaches will</font> not have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot assure</font> you that the <font color="blue">technology</font> we <font color="blue">practice will</font> not infringe     upon the patents of others</td>
    </tr>
    <tr>
      <td>In the event that any future infringement claim     against us is successful, there would be no assurance that we would be         13       ______________________________________________________________________         able to negotiate with the patent holder for a license, in which case we     could be <font color="blue">prevented from practicing</font> the subject matter claimed by the subject     patent</td>
    </tr>
    <tr>
      <td>In addition, there can be no assurance that we would be able to     redesign our products to <font color="blue">avoid infringement</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to practice the     subject matter of patents claimed by others or to redesign its products to     <font color="blue">avoid infringement</font> could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>If we were to fail to obtain <font color="blue"><font color="blue">necessary</font> approvals from</font> the FDA or other     <font color="blue">regulatory</font> agencies, we would not be able to sell our products</td>
    </tr>
    <tr>
      <td>We  must  obtain  certain  approvals  by and marketing clearances from     <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font>, including the FDA and similar health <font color="blue">authorities</font>     in <font color="blue">foreign countries</font> to market and sell our products in those countries</td>
    </tr>
    <tr>
      <td>The     FDA  regulates  the  marketing,  <font color="blue">manufacturing</font>,  labeling,  packaging,     <font color="blue">advertising</font>, sale and <font color="blue">distribution</font> of ‘<font color="blue">medical devices</font>,’ as do various     foreign <font color="blue">authorities</font> in their <font color="blue">respective jurisdictions</font></td>
    </tr>
    <tr>
      <td>The FDA enforces     <font color="blue">additional</font> <font color="blue">regulations</font> regarding the safety of equipment utilizing x-rays</td>
    </tr>
    <tr>
      <td><font color="blue">Various  </font>states  <font color="blue">also impose</font> similar <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our CDR(R) system is     currently regulated by such <font color="blue">authorities</font> and certain of our <font color="blue">new products</font> will     require  approval  by or marketing clearance from various <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">authorities</font>, including the FDA In addition, various <font color="blue">additional</font> <font color="blue">requirements</font>     are <font color="blue">imposed upon us</font> to make us eligible to <font color="blue">sell products</font> to the United     States Government</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">review process typically</font> requires <font color="blue">extended <font color="blue">proceedings</font> pertaining</font> to     the safety and efficacy of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>A 510(k) application is required in     order to market a new or <font color="blue">modified medical</font> device</td>
    </tr>
    <tr>
      <td>If <font color="blue">specifically</font> required     by  the  FDA,  a  pre-market  approval  (“PMA”) may be <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">proceedings</font>,  <font color="blue">which must</font> be completed prior to marketing a new medical     device, are <font color="blue">potentially expensive</font> and time consuming</td>
    </tr>
    <tr>
      <td>They may delay or     hinder a product’s timely entry into the marketplace</td>
    </tr>
    <tr>
      <td>Moreover, there can be     no assurance that the review or <font color="blue">approval process</font> for these <font color="blue">products by</font> the     FDA or any other applicable <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font> will occur in a timely     fashion, if at all, or that <font color="blue">additional</font> <font color="blue">regulations</font> will not be adopted or     current <font color="blue">regulations</font> amended in such a <font color="blue">manner as will <font color="blue">adversely affect</font> us</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">also regulates</font> the content of <font color="blue">advertising</font> and <font color="blue">marketing materials</font>     relating to <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> such <font color="blue">regulations</font> may     result in a delay in obtaining approval for the marketing of <font color="blue">such products</font>     or the withdrawal of <font color="blue">such approval</font> if <font color="blue">previously</font> obtained</td>
    </tr>
    <tr>
      <td>There can be no     assurance  that  our <font color="blue">advertising</font> and <font color="blue">marketing materials</font> regarding our     products are and will be in compliance with such <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We are also     subject  to  other  federal,  state  and  local  laws, <font color="blue">regulations</font> and     <font color="blue">recommendations</font>  relating  to  safe working conditions, laboratory and     <font color="blue">manufacturing</font> practices</td>
    </tr>
    <tr>
      <td>The extent of <font color="blue">government</font> regulation that might     result  from any <font color="blue">future legislation</font> or <font color="blue">administrative action cannot</font> be     <font color="blue">accurately predicted</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> could     have a material adverse effect on us</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>sales of our products     are subject to the <font color="blue">regulatory</font> agency product registration <font color="blue">requirements</font> of     <font color="blue">each country</font> in which our products are sold</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> review process     <font color="blue">varies from country</font> to country and may in some cases require the submission     of <font color="blue">clinical data</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">typically rely on</font> our <font color="blue">distributor</font>s in <font color="blue">foreign countries</font>     to obtain the required <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you, however, that any of the foregoing approvals will be     obtained,  or  that  we  would be able to satisfy any of the foregoing     <font color="blue">requirements</font> on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>Our failure to obtain any of such     approvals or to <font color="blue">comply with</font> any of such <font color="blue">requirements</font> on a <font color="blue">timely basis</font> could     have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Our customers operate in the health     care  industry,  which  is  <font color="blue">highly regulated</font></td>
    </tr>
    <tr>
      <td>Additionally,     cost-containment efforts by health maintenance organizations may adversely     affect the <font color="blue">potential market</font> for our devices</td>
    </tr>
    <tr>
      <td>The need for <font color="blue">warranty service could</font> have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally warrant each</font> of our <font color="blue">products against defects</font> in materials and     workmanship for a period of up to <font color="blue">two years from</font> the date of <font color="blue">shipment plus</font>     any  extended  <font color="blue">warranty period purchased by</font> the customer</td>
    </tr>
    <tr>
      <td>The need for     <font color="blue">warranty service could</font> have a material adverse effect on us by, among other     things, requiring <font color="blue">additional</font> expenditures for parts and <font color="blue">personnel as well as</font>     damaging our reputation and goodwill</td>
    </tr>
    <tr>
      <td>If any product <font color="blue">liability</font> claims were asserted against us or there was a     recall of any of our products, it could have a material adverse effect on     us</td>
    </tr>
    <tr>
      <td>In  addition,  certain  <font color="blue">applications</font>,  including  projected     <font color="blue">applications</font>, of our <font color="blue">products entail</font> the risk of product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Such  risks  will  exist <font color="blue">even with respect</font> to those products that have     received, or in the <font color="blue">future may</font> receive, <font color="blue"><font color="blue">regulatory</font> approval</font> for commercial     sale</td>
    </tr>
    <tr>
      <td>These  claims may be made by consumers, <font color="blue">distributor</font>s or others</td>
    </tr>
    <tr>
      <td>Although we have maintained <font color="blue">insurance coverage</font> related to product <font color="blue">liability</font>     claims, we <font color="blue">cannot assure</font> you that product <font color="blue">liability</font> <font color="blue">insurance coverage</font> will     continue  to be available or, if available, that it can be obtained in     sufficient amounts or at reasonable         14       ______________________________________________________________________         cost or that it will be sufficient to cover any claims that may arise</td>
    </tr>
    <tr>
      <td>We do     not maintain any insurance relating to <font color="blue">potential recalls</font> of our products</td>
    </tr>
    <tr>
      <td>Costs <font color="blue">associated with potential product recalls</font> or product <font color="blue">liability</font> claims     could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>If levels of third-party <font color="blue">reimbursement</font> for <font color="blue">procedures which use</font> our products     were to decline, it could cause our revenues to decline</td>
    </tr>
    <tr>
      <td>Third-party payers, including <font color="blue">government</font> health administration <font color="blue">authorities</font>,     private  health  care  insurers  and  other <font color="blue">organizations regulate</font> the     <font color="blue">reimbursement</font> of fees related to <font color="blue">certain diagnostic procedures</font> or medical     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>Third-party payers are <font color="blue">increasingly challenging</font> the price and     cost-effectiveness of <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict</font>     what effect the policies of <font color="blue">government</font> entities and other third-party payers     will have on future sales of our products, we <font color="blue">cannot assure</font> you that such     <font color="blue">policies would</font> not have a material adverse effect on the Company</td>
    </tr>
    <tr>
      <td>Several factors may <font color="blue">significant</font>ly affect our revenues, expenses and results     of <font color="blue">operations</font> from quarter to quarter, including the timing of new product     <font color="blue">introduction</font>s by us or our <font color="blue">competitors</font>, our ability to <font color="blue">supply products</font> to     meet  <font color="blue">customer demand</font>, and <font color="blue">fluctuations</font> in our <font color="blue">manufacturing</font> costs</td>
    </tr>
    <tr>
      <td>In     addition, our CDR(R) products have been subject to seasonal <font color="blue">variations</font> at     <font color="blue">various times</font> in the past</td>
    </tr>
    <tr>
      <td>Consequently, quarterly results of <font color="blue">operations</font> may     fluctuate</td>
    </tr>
    <tr>
      <td>Such <font color="blue">fluctuations</font> in quarterly results of <font color="blue">operations</font> could     <font color="blue">adversely affect</font> the <font color="blue">market price</font> of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">volatility</font> of the price of our <font color="blue">Common Stock</font> may <font color="blue">adversely affect</font> our     <font color="blue">shareholder</font>s</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market historically</font> has experienced <font color="blue">volatility</font> which has affected     the <font color="blue">market price</font> of securities of many companies and which may be unrelated     to  the operating performance of <font color="blue">such companies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for     securities of medical <font color="blue">technology</font> companies have <font color="blue">historically been highly</font>     volatile</td>
    </tr>
    <tr>
      <td>Future <font color="blue">technological</font> innovations or <font color="blue">new commercial products</font>,     results of <font color="blue">clinical testing</font>, changes in regulation, <font color="blue">litigation</font> and public     <font color="blue">concerns as</font> to product safety as well as period-to-period <font color="blue">fluctuations</font> in     <font color="blue">financial performance</font> and <font color="blue">fluctuations</font> in <font color="blue">securities markets generally could</font>     cause the <font color="blue">market price</font> of the <font color="blue">Common Stock</font> to fluctuate <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>broad market <font color="blue">fluctuations</font> may <font color="blue">adversely affect</font> the <font color="blue">market price</font> of the     <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>We are exposed to risks relating to <font color="blue">evaluations</font> of controls required by     Section 404 of the Sarbanes-Oxley Act of 2002</td>
    </tr>
    <tr>
      <td>We are required under Section 404 of the Sarbanes-Oxley Act to provide a     report on our internal controls over financial reporting to allow <font color="blue">management</font>     to report on, and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm to     attest to, our internal controls</td>
    </tr>
    <tr>
      <td>If we, or the <font color="blue">surviving company following</font>     our  proposed  <font color="blue">combination</font> with Sirona Dental Systems, are not able to     implement  the  <font color="blue">requirements</font> of Section 404 in a <font color="blue">timely manner</font> or with     <font color="blue">adequate compliance</font>, we might be subject to sanctions or <font color="blue">investigation by</font>     <font color="blue">regulatory</font> <font color="blue">authorities</font>, such as the <font color="blue">SEC or the NASDAQ National Market</font></td>
    </tr>
    <tr>
      <td>Any     such action could <font color="blue">adversely affect</font> our financial results or investors’     confidence  in our company and could cause our stock price to fall</td>
    </tr>
    <tr>
      <td>In     addition, our controls and <font color="blue">procedures may</font> not <font color="blue">comply with</font> all the relevant     rules and <font color="blue">regulations</font> of the <font color="blue">SEC and the NASDAQ National Market</font></td>
    </tr>
    <tr>
      <td>If we fail     to develop and maintain <font color="blue">effective controls</font> and procedures, we may be unable     to <font color="blue">provide financial</font> information in a timely and <font color="blue">reliable manner</font></td>
    </tr>
    <tr>
      <td>If we were to <font color="blue">issue preferred stock</font> it might <font color="blue">adversely affect</font> the holders of     our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Certificate of Incorporation </font><font color="blue">authorizes</font> the issuance of a series or     <font color="blue">designation</font> of <font color="blue">Preferred Stock </font>with such rights, preferences, privileges and     <font color="blue">restrictions</font>  as  may  be determined from time to time by our Board of     Directors</td>
    </tr>
    <tr>
      <td>Accordingly, the Board of Directors is empowered, without the     need for <font color="blue">shareholder</font> approval, to issue <font color="blue">Preferred Stock </font><font color="blue">with dividend</font>,     liquidation, conversion, voting or other rights which could <font color="blue">adversely affect</font>     the <font color="blue">voting power</font> or other rights of the holders of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>currently are no shares of <font color="blue">Preferred Stock </font>designated or issued</td>
    </tr>
  </tbody>
</table>